Dermata Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 31 Mar 2026
Net Income -$7.1MTTM through 31 Mar 2026
Free Cash Flow -$8.3MTTM through 31 Mar 2026
Margins
| Current |
|---|
Returns
-28.8%ROE
-24.7%ROA
Balance Sheet Health
Debt / Equity0.00x
Net Debt-$6.9Mnet cash position
Cash & Equivalents$6.9M
Quality Metrics
Earnings-Beat Rate75.0%
Dividend
No dividend
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.